Credit Agricole S A Sells 107,615 Shares of Zoetis Inc. $ZTS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Credit Agricole S A lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 969,716 shares of the company's stock after selling 107,615 shares during the quarter. Zoetis accounts for approximately 0.5% of Credit Agricole S A's portfolio, making the stock its 28th largest position. Credit Agricole S A owned about 0.22% of Zoetis worth $159,664,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Navigoe LLC bought a new position in Zoetis in the 4th quarter valued at about $30,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares in the last quarter. Finally, Bfsg LLC boosted its position in shares of Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after buying an additional 252 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $1.2650 during mid-day trading on Thursday, reaching $155.4950. 2,411,616 shares of the company's stock were exchanged, compared to its average volume of 3,540,633. The firm has a 50-day moving average price of $154.00 and a two-hundred day moving average price of $158.75. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $68.91 billion, a price-to-earnings ratio of 26.76, a price-to-earnings-growth ratio of 2.52 and a beta of 0.88. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.18% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.